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Managing liver disease in pregnancy is both complex and challenging.  Moreover, 
accurate diagnosis is critical to decision making, and often the most significant 
decision is whether to proceed to liver biopsy. Reticence exists among hepatologists 
and radiologists regarding biopsy procedures in this context. With minimal data to 
draw from, experience from single-center series and case reports have formed much 
of the evidence base regarding the safety and efficacy of liver biopsy in pregnancy, 
albeit such reports being largely limited to patients with autoimmune liver diseases.   
 
The publication of a population-based cohort study assessing the pregnancy 
outcomes of women who underwent liver biopsy during pregnancy in the current 
issue of HEPATOLOGY is welcomed, even if some limitations exist in its 
generalizability.[1] By linking data from the Swedish Medical Birth Registry to the 
Swedish Patient Registry, Ludvigsson et al identified 23 women over a twenty-year 
period who had undergone liver biopsy during pregnancy. Seventeen women had a 
diagnosis of a pre-existing liver condition prior to pregnancy, including two women 
who had undergone liver transplantation. Notably, 2/6 biopsies performed in women 
without pre-existing liver disease were for characterization of intrahepatic 
malignancies. By comparing the pregnancy outcomes of the 23 women who 
underwent biopsy during pregnancy, to 1.9 million unexposed pregnancies, 
moderately increased risks of preterm birth and small for gestational age infants 
were identified.   
 
The study focused on births between 1992 and 2011, with hepatitis C virus reported 
as the commonest indication for liver biopsy during pregnancy. The widespread 
availability of transient elastography for the staging of fibrosis and the effectiveness 
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of direct-acting antiviral therapy in achieving virologic ‘cure’ has resulted in liver 
biopsy now being redundant in this context. Furthermore, the majority of women 
underwent biopsy in the first trimester, with more than 50% of biopsies performed in 
the first month of pregnancy. It is likely that many women were unaware of their 
pregnancy at the time of biopsy, making the decision to proceed to biopsy easy for 
the clinicians concerned. Furthermore, it is plausible that a significant number of 
biopsies were deferred to the post-partum period, as the number of biopsies 
undertaken in women with liver disease in the year pre- and post-partum was more 
than fifteen-fold higher (n=384) than those performed during pregnancy.  
 
Chronic liver disease in itself has been shown to have a negative impact on 
pregnancy outcomes, with an increased risk of preterm birth reported in women with 
cirrhosis.[2] In Ludvigsson’s study, when the outcomes of women who underwent 
liver biopsy during pregnancy were compared only to women with pre-existing liver 
disease, the procedure itself was associated with only an increased risk of a small 
for gestational age infant. Notably, women who underwent a liver biopsy in the year 
pre- or post-pregnancy had a greater incidence of adverse pregnancy outcomes, 
with a substantially increased risk of neonatal death, demonstrating the significant 
impact liver disease can have on maternal and fetal health.  
 
The issue of how to investigate the pregnant woman with liver enzyme abnormalities 
or established liver disease (or post liver transplantation) is nuanced, with the 
absolute need for liver biopsy often a source of anxiety. From this study, we can say 
that in the first trimester, liver biopsy appears to be relatively safe and well tolerated. 
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Beyond the first trimester, it is difficult to draw firm conclusions, and each case 
should be judged on the basis of risk and benefit. 
 
If a woman presents for the first time during pregnancy with liver disease, the work-
up is similar to that of the non-pregnant state.[3] A comprehensive history, physical 
exam, and serological testing should yield a diagnosis for the majority. The 
pregnancy related physiological changes lead to dilution of hemoglobin and albumin, 
an elevation in alpha-fetoprotein, and a rise in alkaline phosphatase as a result of 
production by the placenta. Bilirubin, AST, ALT, GGT, and PT/INR remain largely 
unchanged and may assist in determining both the etiology and severity of the 
underlying disease. Ultrasound is safe and remains the imaging modality of choice.  
 
An assessment of liver fibrosis by non-invasive methods may also be useful to 
assess for chronicity of liver disease, and data is slowly emerging on the safety of 
transient elastography and acoustic radiation force impulse (ARFI) elastosonography 
in pregnant women. Further validation will be necessary to accurately characterize 
the changes in liver elasticity that occur during pregnancy and evaluate the impact of 
pregnancy related conditions such as pre-eclampsia.[4] Non-invasive scores have 
been shown in a number of studies to have a reasonable correlation with the 
histological assessment of liver fibrosis. [5] However, platelet counts decrease during 
pregnancy, so although the APRI and FIB-4 score may assist in the identification of 
patients with cirrhosis, their positive predictive value will fall.  
 
First performed in Germany in 1882, and refined by Menghini to the "one-second 
needle biopsy of the liver" technique in 1958, percutaneous liver biopsy allows 
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accurate assessment of both liver injury and fibrosis, as well as the enabling the 
histopathological characterization of tumors.[6] Large cohort studies have 
demonstrated the safety of the procedure in non-pregnant patients, with a low rate of 
complications, and a procedural associated mortality of 1/10,000. The major risk is 
post-biopsy hemorrhage, which is increased in patients with significant 
thrombocytopenia.[7]  
 
In reality, for women with a suspected pregnancy associated liver disease, liver 
biopsy should only rarely be necessary, as these conditions tend to have 
characteristic features in terms of clinical presentation, alterations in laboratory 
indices and trimester of occurrence. Acute fatty liver of pregnancy has the greatest 
impact on maternal and fetal health, and although liver biopsy was previously 
considered essential for confirmation of the characteristic microvesicular steatosis 
present on histology, biopsy was associated with a significant risk of bleeding in 
patients with coagulopathy. In recent years, validation of the non-invasive ‘Swansea 
criteria’ for diagnosis has largely eliminated the need for biopsy, except in cases 
where there is clinical uncertainty or an atypical presentation of the disease.[8] 
 
Liver biopsy is most likely to be indicated during pregnancy for selected women with 
pre-existing liver disease, where the disease is likely to cause significant risk to 
mother or fetus. A priori, this includes 1) women with a suspicious liver lesion, 2) 
women with coincident seronegative disease (i.e. suspected autoimmune or other 
unexplained hepatitis with negative autoantibodies and normal immunoglobulin G 
levels), or 3) women who have undergone liver transplantation with significant graft 
dysfunction and unrevealing viral and immune serology. Cardiac output increases 
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during pregnancy, but hepatic blood flow does not alter significantly, and there were 
no instances of post biopsy hemorrhage reported in Ludvigsson’s study.[9] Potential 
risks to the fetus from procedural sedation were not explored, but the literature to 
date would indicate that for a single short procedure, the use of sedation is unlikely 
to lead to significant neurological sequelae.[10] 
 
To conclude, the data presented in this retrospective cohort study provides support 
for the safety of liver biopsy in selected women during pregnancy. Important caveats 
remain. As the majority of women were biopsied in the first trimester of pregnancy, 
and over half in the first month after conception, the results are not generalizable to 
women in the later stages of pregnancy. Furthermore, although it is likely that the 
overwhelming majority of these biopsies were undertaken by the percutaneous 
route, this has not been confirmed by the authors. For women presenting with liver 
disease in later pregnancy, the risks and benefits of performing a liver biopsy must 
be carefully weighed against expectant management, with a view to liver biopsy in 
the post-partum period.  
 
Figure: Workup of abnormal liver function tests in pregnancy  
 
Figure Legend: 
T: Trimester  
HELLP: Hemolysis, elevated liver enzymes, and low platelets;  
ARFI: acoustic radiation force impulse elastosonography  
  
Page 7 of 10
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
References  
1.  Ludvigsson JF, Marschall HU, Hagstrom H, et al. Pregnancy Outcome in 
Women Undergoing Liver Biopsy During Pregnancy: A Nationwide Population-
Based Cohort Study. Hepatology. 2017;doi: 10.1002/hep.29345. [Epub ahead 
of print].  
2.  Westbrook RH, Yeoman AD, O’Grady JG, et al. Model for End-Stage Liver 
Disease Score Predicts Outcome in Cirrhotic Patients During Pregnancy. Clin 
Gastroenterol Hepatol. 2011;9(8):694–9.  
3.  Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and 
Pregnancy. Am J Gastroenterol. 2016;111(2):176–94.  
4.  Kohlhaas A, Millonig G, Schütz F, et al. Liver stiffness during pregnancy 
[Abstract 336]. J Hepatol. 2011;54(Suppl 1):S134–S135.  
5.  Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient 
elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in 
chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.  
6.  Menghini G. One-second needle biopsy of the liver. Gastroenterology. 
1958;35(2):190–9.  
7.  Boyum JH, Atwell TD, Schmit GD, et al. Incidence and Risk Factors for 
Adverse Events Related to Image-Guided Liver Biopsy. Mayo Clin Proc. 
2016;91(3):329–35.  
8.  Goel A, Ramakrishna B, Zachariah U, et al. How accurate are the Swansea 
criteria to diagnose acute fatty liver of pregnancy in predicting hepatic 
microvesicular steatosis? Gut. 2011;60(1):138–9.  
9.  Robson SC, Mutch E, Boys RJ, et al. Apparent liver blood flow during 
pregnancy: a serial study using indocyanine green clearance. Br J Obstet 
Page 8 of 10
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
Gynaecol. 1990;97(8):720–4.  
10.  Andropoulos D, Greene M. Anesthesia and Developing Brains - Implications of 
the FDA Warning. N Engl J Med. 2017;376(10):905–7.  
 
Page 9 of 10
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  
 
 
Workup of abnormal liver function tests in pregnancy  
 
338x190mm (300 x 300 DPI)  
 
 
Page 10 of 10
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
